Agents Assemble: When Multi‑Agent LLMs Stop Hallucinating and Start Doing Science
Opening — Why this matters now Drug discovery is slow, expensive, and statistically brutal. The industry’s median timeline from hypothesis to approval can stretch a decade, and the probability of late‑stage failure still hovers at depressing levels. Meanwhile, clinicians sit on vast biological insight they cannot operationalize because the computational tools remain locked behind specialist workflows. ...